Daily as of 3 Nov 16:00 ET
- Price
- below both $20.57 vs 50 $23.38 / 200 $23.62
- Projection
- No cross projected
- Test
- Cross test window open, no test bar yet
- Last cross
- 💀Death cross 2 Nov 2026 · projected 29 bars out
ACAD | Acadia PharmaceuticalsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$20.57
+$0.10 (+0.49%)
Acadia Pharmaceuticals (ACAD) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2017.
The 50 SMA has sat below the 200 on the daily since Nov 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the weekly, price sits below the 50 and the 200; on the 4-hour it is between the two.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- below both $20.59 vs 50 $24.02 / 200 $21.53
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross week of 10 Nov 2025 · projected 27 bars out
4-hour as of 3 Nov 13:30 ET
- Price
- between the two $20.77 vs 50 $19.91 / 200 $24.70
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 💀Death cross 6 Oct 2026 · projected 25 bars out
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| 2 Nov 2026 | 💀Death steep | daily | 29 bars out | Active Cross Test |
| 6 Oct 2026 | 💀Death | 4-hour | 25 bars out | Not tested |
| 31 Jul 2026 | 🟨Golden moderate | daily | 26 bars out | Not tested |
| 1 Jul 2026 | 🟨Golden | 4-hour | 19 bars out | Not tested |
| 25 Mar 2026 | 💀Death steep | daily | 18 bars out | Not tested |
About ACAD
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$38.5M
4-hour coverageYes, since Oct 2025
History on recordSince 2017
SectorHealthcare
Cap bandmid